Diffuse large B-cell lymphoma
Conditions
Interventions
Diffuse large B-cell lymphoma group:Obrutinib, lenalidomide and rituximab were given
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Cd20-positive diffuse large B-cell lymphoma independently diagnosed by two pathologists; 2. Age >=65, both sexes; 3. Patients who had received at least one previous treatment failure (including immunochemotherapy, chemotherapy, or hematopoietic stem cell transplantation) with no response or a first recurrence after remission; 4. Before starting treatment, comprehensive geriatric assessment (IACA index) was performed, including patients' age, Instrumental Assessment of Activities of daily Living (IADL score), Charlson comorbidibility index (CCI score), and serum albumin level. Patients with IACA score >=1 were defined as ineligible for standard immunochemotherapy, specifically as Instrumental Assessment of Activities of daily Living Scale (IADL) =3, or age >75 years; 5. The estimated survival time is more than 3 months; 6. Patients were informed about this study and signed written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with previous history of hematologic (non-lymphoma) or non-hematologic tumors undergoing chemoradiotherapy 2. There's a serious infection that's not under control 3. Known bleeding tendencies or hemophilia 4. Poor compliance 5. Not suitable considered by the researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;Progression free survival; | — |
Countries
China
Contacts
Public ContactLiu Hui
Beijing Hospital
Outcome results
None listed